Literature DB >> 2423232

Differential effects of selenium on normal and neoplastic canine mammary cells.

M E Fico, K A Poirier, A M Watrach, M A Watrach, J A Milner.   

Abstract

Four different canine mammary tumor (CMT) cell lines and a nonneoplastic primary culture of mammary cells were examined for their in vitro responsiveness to selenium supplementation. These cell lines were found to vary in their metabolic response to increasing concentrations of selenium. Sensitivity to selenium, as sodium selenite, increased with increasing concentrations of this trace element in all of the neoplastic lines. These data also suggest that increasing the plating density of tumor cells further increases the sensitivity to selenium. A relatively selenium-sensitive cell line (CMT-13) and relatively insensitive cell line (CMT-11) were characterized on the basis of reduced growth resulting from selenium supplementation. Increasing the concentration of selenium to 0.75 microgram/ml depressed the growth of CMT-13 and CMT-11 cells by 75% and 11%, respectively, while no inhibition was observed in nonneoplastic cells. These cell lines also varied in their sensitivity to different forms of selenium. Selenodiglutathione was the most effective form of selenium examined that inhibited tumor cell growth. The sensitivity of the neoplastic lines was selenodiglutathione much greater than sodium selenite much greater than selenocystine greater than selenomethionine. None of the forms of selenium examined inhibited the growth of the nonneoplastic mammary cells in culture. Supplementation with sodium selenite (1 microgram Se per ml) for 60 min resulted in a dramatic depression in RNA biosynthesis in CMT-13, but not CMT-11 or nonneoplastic cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2423232

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Products of the reaction of selenite with intracellular sulfhydryl compounds.

Authors:  G D Frenkel; D Falvey; C MacVicar
Journal:  Biol Trace Elem Res       Date:  1991-07       Impact factor: 3.738

2.  Intracellular distribution of selenium and the growth of mammary cells in culture.

Authors:  K Hwang; J A Milner
Journal:  Biol Trace Elem Res       Date:  1996-02       Impact factor: 3.738

3.  Effect of selenium on the growth of three human colon cancer cell lines.

Authors:  J L Nano; D Czerucka; F Menguy; P Rampal
Journal:  Biol Trace Elem Res       Date:  1989 Apr-May       Impact factor: 3.738

Review 4.  Chemopreventive mechanisms of selenium.

Authors:  G F Combs
Journal:  Med Klin (Munich)       Date:  1999-10-15

5.  Protective effects of selenocystine against γ-radiation-induced genotoxicity in Swiss albino mice.

Authors:  Amit Kunwar; S Jayakumar; H N Bhilwade; P P Bag; H Bhatt; R C Chaubey; K I Priyadarsini
Journal:  Radiat Environ Biophys       Date:  2011-01-23       Impact factor: 1.925

6.  Modulation of redox status in human lung cell lines by organoselenocompounds: selenazolidines, selenomethionine, and methylseleninic acid.

Authors:  Robyn L Poerschke; Michael R Franklin; Philip J Moos
Journal:  Toxicol In Vitro       Date:  2008-08-15       Impact factor: 3.500

7.  Effects of selenomethionine on cell growth and on S-adenosylmethionine metabolism in cultured malignant cells.

Authors:  E O Kajander; R J Harvima; L Kauppinen; K K Akerman; H Martikainen; R L Pajula; S O Kärenlampi
Journal:  Biochem J       Date:  1990-05-01       Impact factor: 3.857

8.  Chemical form of selenium greatly affects metal uptake and responses by cultured human lymphocytes.

Authors:  P Borella; A Bargellini; C I Medici
Journal:  Biol Trace Elem Res       Date:  1996-01       Impact factor: 3.738

Review 9.  Cancer risk from inorganics.

Authors:  S H Swierenga; J P Gilman; J R McLean
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 10.  Selenium. Preclinical studies of anticancer therapeutic potential.

Authors:  G Batist
Journal:  Biol Trace Elem Res       Date:  1988 Jan-Apr       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.